In a study presented at ASCO, researchers found that the drug duloxetine (Cymbalta) can help to treat peripheral neuropathy, a painful side effect of chemotherapy using taxanes. Taxotere, the chemotherapy drug used to treat castrate resistant, advanced prostate cancer is a taxane. Peripheral neuropathy occurs when nerves in the body's peripheral nervous system (outside the [...]
At the American Society for Clinical Oncology's (ASCO) meeting there was an upsetting plenary presentation made on June 3. Data was presented by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center. Dr. Hussain discussed the findings from the phase III clinical trial SWOG-9346, the largest such study to date [...]
Today, May 16, 2012, Dendreon, the makers of Provenge, disclosed a new analysis of data of its pivotal 512-patient study of men with castrate resistant prostate cancer who received sipuleucel-T (Provenge). The new analysis separated the men in the study into four quartiles based on their prostate-specific antigen (PSA) scores. The initial design of the [...]
Understanding and deciding on appropriate treatments for men with advanced prostate cancer can be confusing. All the treatments come with side effects and one never knows what the benefits might be for an individual. Even with good clinical trials, men with advanced prostate cancer still need to navigate a most unclear path. Provenge, ever since [...]
Denosumab (Xgeva), the recently approved and only therapy that prolongs bone metastasis-free survival in men with non-metastatic castrate-resistant prostate cancer (CRPC) who are at high risk for the spread of prostate cancer metastasis to bone seems to work best in men with very rapid prostate specific antigen (PSA) kinetics. The large 1,432 man, placebo controlled, [...]
Abstract No:101 at the recent ASCO Conference It is sad, but it is true, a subset of men presenting with advanced prostate cancer never receive proper therapy. This can be attributed to a variety of factors including poor functional status, co-morbidities, and patient preference. The researchers sought to determine the prevalence, and characteristics, of this [...]
At the 2012 Genitourinary Cancers Symposium ASCO conference, Dr. Philip Kantoff (Dana-Farber Cancer Institute, Harvard Medical School Boston, MA) suggested taking a personalized approach to the individualized treatment plan for all men suffering from advanced prostate cancer. Dr. Kantoff said, “Few patients with advanced prostate cancer are currently cured with ADT (but anecdotally, long-term survival [...]
The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]
Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented [...]
